SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.23+0.21 (+5.22%)
Close on Oct 19, 2026
- Market cap
- $420.09M
- P/E (TTM)
- –
- Dividend yield
- –
ARS Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $420.66M | $166.30M |
| Enterprise Value | $276.82M | $88.19M |
| PS Ratio | 3.60 | 3.65 |
| PB Ratio | 33.62 | 2.03 |
Enterprise value
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.37 | 2.51 |
Income (trailing twelve months)
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $116.93M | $58.34M |
| Operating Income | -$216.27M | -$21.40M |
| Net Income | -$215.43M | -$22.46M |
| EBITDA | -$214.65M | -$16.91M |
| EPS (Diluted) | -$2.18 | -$0.83 |
Margins
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -185.0% | -44.0% |
| Profit Margin | -184.2% | -40.2% |
| EBITDA Margin | -183.6% | -30.2% |
| FCF Margin | -168.1% | -9.27% |
Returns
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -210.3% | -53.2% |
| Return on Assets (ROA) | -76.5% | -40.9% |
| Return on Capital Employed (ROCE) | -114.7% | -38.1% |
Growth
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 4.08% | 5.96% |
| Revenue Growth (3Y CAGR) | 300.1% | 2.25% |
Balance sheet
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $143.85M | $61.43M |
| Net Cash (Debt) | $143.85M | $15.35M |
| Net Cash Per Share | $1.45 | $0.66 |
| Equity (Book Value) | $12.51M | $49.09M |
| Book Value Per Share | $0.13 | $1.37 |
| Tangible Book Value | -$1.39M | $23.52M |
| Working Capital | $150.65M | $76.81M |
Financial position
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.48 | 3.34 |
| Quick Ratio | 3.13 | 2.44 |
Cash flow (trailing twelve months)
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$196.41M | -$12.35M |
| Capital Expenditures | -$197.00K | -$1.08M |
| Free Cash Flow | -$196.60M | -$20.22M |
| FCF Per Share | -$1.98 | -$0.42 |
Efficiency
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.42 | 0.39 |
| Revenue Per Employee | $740.04K | $404.87K |
| Profits Per Employee | -$1.36M | -$703.34K |
| Employee Count | 158 | 74 |
Dividends and yields
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -51.2% | -23.3% |
| FCF Yield | -46.7% | -8.72% |
Shares
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 99,447,300 | 58,127,000 |
| Shares Change (YoY) | -3.93% | 10.9% |
| Shares Change (QoQ) | 0.14% | 0.54% |
| Float | 52,965,500 | 49,136,700 |
| Shares Held by Insiders | 46.7% | 11.6% |
| Shares Held by Institutions | 91.2% | 59.4% |
Scores
| Measure | ARS Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -2.95 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from ARS Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.